Another legal salvo has been fired against top insulin makers, accusing them of colluding on prices, but this class action suit also targets pharmacy benefit managers CVS, Express Scripts and UnitedHealth’s OptumRx, claiming they were part of the alleged scheme.
The leading U.S. drugmakers and pharmacy benefit managers colluded to fix prices for insulin, leading to skyrocketing costs and windfall profits for the companies, a new lawsuit alleges.
Pharmacy benefit managers and tech startups are responding to underinsurance and the onslaught of high-deductible health plans by cutting out insurers in the quest to help patients lower their prescription drug costs.
This week, Novo Nordisk and CVS Health announced a new program that will offer discounts on insulin, a life-sustaining drug for people with diabetes.
Insulin prices have been rising — increases that mean some people are spending as much on monthly diabetes-related expenses as their mortgage payment.
Sen. Bernie Sanders, I-VT, an outspoken critic of the pharmaceutical industry, lobbed his latest attack on Monday, this time at television news networks for their lack of coverage on rising drug prices.
Too many diabetics in the U.S. are inadvertently getting stuck with a big bill, making it imperative that drugmakers and middlemen at the heart of the country’s complex pricing system fix the issue before regulators step in, the world’s biggest maker of insulin said.
James Elliott is convinced that the statistics describing the prevalence of type 1 diabetes are misleading.
I’m a Type 1 diabetic, and I was diagnosed at 13 years old.
For underinsured Americans, insurance won’t cover the cost of prescription medications.
Between 2002 and 2013, the number of Americans diagnosed with diabetes increased by approximately 65%, from 13.5 million to 22.3 million.
A federal lawsuit is accusing three of the biggest drug manufacturers of insulin of conspiring together to raise their prices, but the pharmaceutical companies deny the allegations.